Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium


HOLON, Israel, Jan. 14, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, will be featured in a trial-in-progress poster at The ASCO-SITC Clinical Immuno-Oncology Symposium, taking place February 28-March 2, 2019, in San Francisco, CA.

The poster titled "A Phase 1 Study Evaluating COM701 in Patients With Advanced Solid Tumors," will be presented by Drew W. Rasco, M.D, Associate Director of Clinical Research at the South Texas Accelerated Research Therapeutics (START), San Antonio, TX and a Principal Investigator in the Phase 1 COM701 study. 

The poster abstract is expected to be published on the conference website on February 25, 2019, and will reflect enrolment information as of the date of the abstract submission. The poster presentation will take place on Thursday, February 28, 2019, and will include updated enrolment information.

The poster will be available on Compugen's website at www.cgen.com following the conference presentation.

About Compugen

Compugen is a clinical-stage, therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel with R&D facilities in both Israel and South San Francisco, CA.Compugen's ordinary shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.

Forward-Looking Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and describe opinions about possible future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors, including the ability to finance the Company, are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Company contact:  

Elana Holzman   

Director, Investor Relations and Corporate Communications  

Compugen Ltd. 

Email: elanah@cgen.com   

Tel: +972 (3) 765-8124

Investor Relations contact: 

Burns McClellan, Inc.  

Jill Steier

Email: jsteier@burnsmc.com 

Tel: 212-213-0006

 

 

View original content:http://www.prnewswire.com/news-releases/compugens-phase-1-trial-of-com701-featured-as-a-trial-in-progress-at-the-asco-sitc-clinical-immuno-oncology-symposium-300777515.html

SOURCE Compugen Ltd.